Skip to content

Study · Observational study · n = 25,804 · 2026

4 results

Real-World Effectiveness of Semaglutide and Tirzepatide Compared With Bariatric Surgery.

Brown A, Patel SS, Kozato A, Orandi BJ, Massie A, Vu AH, Somoza E, Mei T, Desai S, Zhang DS, Segev D, Welcome AU, Ren-Fielding C, Parikh M, Chhabra KR

Obesity (Silver Spring, Md.)25 Jun 2026

PMID42345739 (opens in a new tab)PMCIDPMC13422669 (opens in a new tab)DOI10.1002/oby.70246 (opens in a new tab)PepBankPUB-42345739
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In adults with BMI of 35 or more, semaglutide gave total weight loss of 5.4% to 7.4% over 1 to 3 years, less than bariatric surgery (intention-to-treat).

    In plain wordsIn adults with severe obesity, semaglutide led to less weight loss over 3 years than weight-loss surgery.

    Peptide
    Semaglutide
    Outcome
    DecreaseTotal weight loss
    Study

    n = 25,804

    Comparator
    Bariatric surgery (sleeve gastrectomy, gastric bypass)
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Total weight loss
    5.4%
    year 1
    Total weight loss
    6.5%
    year 2
    Total weight loss
    7.4%
    year 3

    Source sentences

    Summary
    semaglutide (n = 25,804) TWL (95% CI): 5.4% (5.3%-5.6%), 6.5% (6.4%-6.7%), and 7.4% (7.3%-7.6%)
    3 context sentences
    Summary · context
    Of 44,025 patients studied, bariatric surgery was associated with greater weight loss at 1, 2, and 3 years post treatment
    Summary · context
    This study included adults with BMI ≥ 35 who received injectable semaglutide or tirzepatide (GLP-1RAs) or sleeve gastrectomy or gastric bypass (bariatric surgery) at two urban health systems from 2018 to 2024.
    Summary · context
    Total weight loss (TWL) was compared up to 3 years post treatment with inverse probability weighting and mixed linear models.
  2. 02HumanObservational studyEfficacy outcome

    In adults with BMI of 35 or more, tirzepatide gave total weight loss of 9.1% to 10.8% over 1 to 2 years, less than bariatric surgery (intention-to-treat).

    In plain wordsIn adults with severe obesity, tirzepatide led to less weight loss over 2 years than weight-loss surgery.

    Peptide
    Tirzepatide
    Outcome
    DecreaseTotal weight loss
    Study

    n = 7,308

    Comparator
    Bariatric surgery (sleeve gastrectomy, gastric bypass)
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Total weight loss
    9.1%
    year 1
    Total weight loss
    10.8%
    year 2

    Source sentences

    Summary
    tirzepatide (n = 7308): 9.1% (8.9%-9.4%) and 10.8% (10.2%-11.3%)
    3 context sentences
    Summary · context
    Of 44,025 patients studied, bariatric surgery was associated with greater weight loss at 1, 2, and 3 years post treatment
    Summary · context
    This study included adults with BMI ≥ 35 who received injectable semaglutide or tirzepatide (GLP-1RAs) or sleeve gastrectomy or gastric bypass (bariatric surgery) at two urban health systems from 2018 to 2024.
    Summary · context
    Total weight loss (TWL) was compared up to 3 years post treatment with inverse probability weighting and mixed linear models.
  3. 03HumanObservational studyEfficacy outcome

    In adults with BMI of 35 or more with 1 year of continuous GLP-1RA, semaglutide gave total weight loss of 7.2% to 8.8% over 1 to 3 years (per-protocol).

    In plain wordsIn adults with severe obesity who stayed on semaglutide for a year, weight loss reached 8.8% by year 3.

    Peptide
    Semaglutide
    Outcome
    DecreaseTotal weight loss
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Total weight loss
    7.2%
    year 1
    Total weight loss
    8%
    year 2
    Total weight loss
    8.8%
    year 3

    Source sentences

    Summary
    semaglutide TWL: 7.2% (7.0%-7.4%), 8.0% (7.8%-8.2%), and 8.8% (8.6%-9.0%)
    3 context sentences
    Summary · context
    Intention-to-treat (any GLP-1RA) and per-protocol (1 year of continuous GLP-1RA orders) analyses were performed.
    Summary · context
    This study included adults with BMI ≥ 35 who received injectable semaglutide or tirzepatide (GLP-1RAs) or sleeve gastrectomy or gastric bypass (bariatric surgery) at two urban health systems from 2018 to 2024.
    Summary · context
    Total weight loss (TWL) was compared up to 3 years post treatment with inverse probability weighting and mixed linear models.
  4. 04HumanObservational studyEfficacy outcome

    In adults with BMI of 35 or more with 1 year of continuous GLP-1RA, tirzepatide gave total weight loss of 11.7% to 11.9% over 1 to 2 years (per-protocol).

    In plain wordsIn adults with severe obesity who stayed on tirzepatide for a year, weight loss was 11.7% at year 1 and 11.9% at year 2.

    Peptide
    Tirzepatide
    Outcome
    DecreaseTotal weight loss
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Total weight loss
    11.7%
    year 1
    Total weight loss
    11.9%
    year 2

    Source sentences

    Summary
    tirzepatide TWL: 11.7% (11.4%-11.9%) and 11.9% (11.5%-12.3%).
    3 context sentences
    Summary · context
    Intention-to-treat (any GLP-1RA) and per-protocol (1 year of continuous GLP-1RA orders) analyses were performed.
    Summary · context
    This study included adults with BMI ≥ 35 who received injectable semaglutide or tirzepatide (GLP-1RAs) or sleeve gastrectomy or gastric bypass (bariatric surgery) at two urban health systems from 2018 to 2024.
    Summary · context
    Total weight loss (TWL) was compared up to 3 years post treatment with inverse probability weighting and mixed linear models.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:07 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.